Genprex (GNPX) Competitors $0.44 -0.03 (-6.39%) Closing price 02/14/2025 04:00 PM EasternExtended Trading$0.43 -0.01 (-2.25%) As of 02/14/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends GNPX vs. OKUR, COCP, CARM, MIRA, ATHA, DWTX, MEIP, FNCH, MRKR, and CDIOShould you be buying Genprex stock or one of its competitors? The main competitors of Genprex include OnKure Therapeutics (OKUR), Cocrystal Pharma (COCP), Carisma Therapeutics (CARM), MIRA Pharmaceuticals (MIRA), Athira Pharma (ATHA), Dogwood Therapeutics (DWTX), MEI Pharma (MEIP), Finch Therapeutics Group (FNCH), Marker Therapeutics (MRKR), and Cardio Diagnostics (CDIO). These companies are all part of the "pharmaceutical products" industry. Genprex vs. OnKure Therapeutics Cocrystal Pharma Carisma Therapeutics MIRA Pharmaceuticals Athira Pharma Dogwood Therapeutics MEI Pharma Finch Therapeutics Group Marker Therapeutics Cardio Diagnostics OnKure Therapeutics (NASDAQ:OKUR) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, community ranking, valuation and profitability. Which has better valuation & earnings, OKUR or GNPX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOnKure TherapeuticsN/AN/A-$77.39M-$12.20-0.47GenprexN/AN/A-$30.86MN/AN/A Does the media favor OKUR or GNPX? In the previous week, OnKure Therapeutics and OnKure Therapeutics both had 4 articles in the media. OnKure Therapeutics' average media sentiment score of 0.81 beat Genprex's score of -0.08 indicating that OnKure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OnKure Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genprex 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of OKUR or GNPX? 91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 17.9% of OnKure Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Genprex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate OKUR or GNPX? OnKure Therapeutics currently has a consensus price target of $36.00, suggesting a potential upside of 527.18%. Genprex has a consensus price target of $10.00, suggesting a potential upside of 2,168.09%. Given Genprex's higher probable upside, analysts clearly believe Genprex is more favorable than OnKure Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OnKure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40Genprex 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in OKUR or GNPX? Genprex received 194 more outperform votes than OnKure Therapeutics when rated by MarketBeat users. However, 100.00% of users gave OnKure Therapeutics an outperform vote while only 65.25% of users gave Genprex an outperform vote. CompanyUnderperformOutperformOnKure TherapeuticsOutperform Votes5100.00% Underperform VotesNo VotesGenprexOutperform Votes19965.25% Underperform Votes10634.75% Which has more volatility and risk, OKUR or GNPX? OnKure Therapeutics has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, Genprex has a beta of -0.96, suggesting that its share price is 196% less volatile than the S&P 500. Is OKUR or GNPX more profitable? OnKure Therapeutics' return on equity of -51.17% beat Genprex's return on equity.Company Net Margins Return on Equity Return on Assets OnKure TherapeuticsN/A -51.17% -47.11% Genprex N/A -409.48%-269.17% SummaryOnKure Therapeutics beats Genprex on 10 of the 13 factors compared between the two stocks. Get Genprex News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNPX vs. The Competition Export to ExcelMetricGenprexPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.75M$6.85B$5.77B$9.21BDividend YieldN/A2.88%5.27%3.99%P/E RatioN/A9.0525.6519.13Price / SalesN/A318.75475.1180.74Price / CashN/A75.4646.0638.90Price / Book0.095.537.275.05Net Income-$30.86M$123.46M$3.19B$222.81M7 Day Performance-10.51%1.37%1.67%1.29%1 Month Performance-38.76%2.09%4.11%1.52%1 Year Performance-89.98%1.28%22.10%16.53% Genprex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNPXGenprex4.5191 of 5 stars$0.44-6.4%$10.00+2,168.1%-90.0%$3.75MN/A0.0020Short Interest ↓Gap DownHigh Trading VolumeOKUROnKure Therapeutics3.3822 of 5 stars$5.85-5.0%$36.00+515.9%N/A$19.59MN/A-0.48N/ACOCPCocrystal Pharma3.5694 of 5 stars$1.91-4.2%$7.00+267.3%+23.0%$19.48MN/A-1.0410Positive NewsGap DownCARMCarisma Therapeutics3.3958 of 5 stars$0.47+1.1%$4.94+962.4%-78.6%$19.41M$14.92M-0.3020Gap DownMIRAMIRA Pharmaceuticals2.5115 of 5 stars$1.16-3.8%$14.00+1,112.1%+11.5%$19.19MN/A-2.072Positive NewsATHAAthira Pharma3.6034 of 5 stars$0.49-6.7%$13.83+2,723.1%-86.9%$18.95MN/A-0.1740Upcoming EarningsShort Interest ↓Positive NewsDWTXDogwood TherapeuticsN/A$14.29+14.4%N/AN/A$18.84MN/A-2.165Gap DownMEIPMEI Pharma4.5513 of 5 stars$2.79-2.3%$7.00+151.3%-38.7%$18.55M$65.30M-0.40100Earnings ReportPositive NewsGap DownFNCHFinch Therapeutics GroupN/A$11.39+1.2%N/A+500.0%$18.34M$110,000.00-1.29190MRKRMarker Therapeutics4.3778 of 5 stars$1.69-8.1%$19.00+1,023.6%-58.0%$18.31M$3.31M0.0060Short Interest ↑Gap DownCDIOCardio Diagnostics2.0959 of 5 stars$0.44+0.9%$2.00+351.5%-62.4%$17.92M$20,000.000.001Negative News Related Companies and Tools Related Companies OKUR Competitors COCP Competitors CARM Competitors MIRA Competitors ATHA Competitors DWTX Competitors MEIP Competitors FNCH Competitors MRKR Competitors CDIO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GNPX) was last updated on 2/17/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredTop Picks for Trump’s Pro-Crypto America10,000% Crypto Opportunities in 2025 27 of the brightest minds in crypto share exclusive intel… Crypto 101 Media | SponsoredHe called the top and bottom of Bitcoin nearly to the day … Here’s what he says is next.With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genprex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.